Recent Advances in Antiviral Therapy for Chronic Hepatitis C
Hepatitis C virus (HCV) infection is a major worldwide health problem. Chronic infection induces continuous inflammation in the liver, progression of hepatic fibrosis, eventual cirrhosis, and possible hepatocellular carcinoma. Eradication of the virus is one of the most important treatment aims. A n...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2016/6841628 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551561862053888 |
|---|---|
| author | Akihiro Tamori Masaru Enomoto Norifumi Kawada |
| author_facet | Akihiro Tamori Masaru Enomoto Norifumi Kawada |
| author_sort | Akihiro Tamori |
| collection | DOAJ |
| description | Hepatitis C virus (HCV) infection is a major worldwide health problem. Chronic infection induces continuous inflammation in the liver, progression of hepatic fibrosis, eventual cirrhosis, and possible hepatocellular carcinoma. Eradication of the virus is one of the most important treatment aims. A number of promising new direct-acting antivirals (DAAs) have been developed over the past 10 years. Due to their increased efficacy, safety, and tolerability, interferon-free oral therapies with DAAs have been approved for patients with HCV, including those with cirrhosis. This review introduces the characteristics and results of recent clinical trials of several DAAs: NS3/4A protease inhibitors, NS5A inhibitors, and NS5B inhibitors. DAA treatment failure and prognosis after DAA therapy are also discussed. |
| format | Article |
| id | doaj-art-bc372726d05d49dba51b8686ba33c297 |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-bc372726d05d49dba51b8686ba33c2972025-02-03T06:01:15ZengWileyMediators of Inflammation0962-93511466-18612016-01-01201610.1155/2016/68416286841628Recent Advances in Antiviral Therapy for Chronic Hepatitis CAkihiro Tamori0Masaru Enomoto1Norifumi Kawada2Department of Hepatology, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, JapanDepartment of Hepatology, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, JapanDepartment of Hepatology, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, JapanHepatitis C virus (HCV) infection is a major worldwide health problem. Chronic infection induces continuous inflammation in the liver, progression of hepatic fibrosis, eventual cirrhosis, and possible hepatocellular carcinoma. Eradication of the virus is one of the most important treatment aims. A number of promising new direct-acting antivirals (DAAs) have been developed over the past 10 years. Due to their increased efficacy, safety, and tolerability, interferon-free oral therapies with DAAs have been approved for patients with HCV, including those with cirrhosis. This review introduces the characteristics and results of recent clinical trials of several DAAs: NS3/4A protease inhibitors, NS5A inhibitors, and NS5B inhibitors. DAA treatment failure and prognosis after DAA therapy are also discussed.http://dx.doi.org/10.1155/2016/6841628 |
| spellingShingle | Akihiro Tamori Masaru Enomoto Norifumi Kawada Recent Advances in Antiviral Therapy for Chronic Hepatitis C Mediators of Inflammation |
| title | Recent Advances in Antiviral Therapy for Chronic Hepatitis C |
| title_full | Recent Advances in Antiviral Therapy for Chronic Hepatitis C |
| title_fullStr | Recent Advances in Antiviral Therapy for Chronic Hepatitis C |
| title_full_unstemmed | Recent Advances in Antiviral Therapy for Chronic Hepatitis C |
| title_short | Recent Advances in Antiviral Therapy for Chronic Hepatitis C |
| title_sort | recent advances in antiviral therapy for chronic hepatitis c |
| url | http://dx.doi.org/10.1155/2016/6841628 |
| work_keys_str_mv | AT akihirotamori recentadvancesinantiviraltherapyforchronichepatitisc AT masaruenomoto recentadvancesinantiviraltherapyforchronichepatitisc AT norifumikawada recentadvancesinantiviraltherapyforchronichepatitisc |